Total Voting Rights and Admission of Shares
Summary by AI BETAClose X
1 May 2026
Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
Total Voting Rights
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 April 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,995,630 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,995,630.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.
|
1 |
Details of the issuer |
|
|
a) |
Name |
AstraZeneca PLC |
|
b) |
LEI |
PY6ZZQWO2IZFZC3IOL08 |
|
2 |
Details of the transferable securities admitted to trading |
|
|
a) |
Name, type and identification code |
Ordinary Shares of $0.25 each ISIN: GB0009895292 |
|
b) |
Regulated market |
London Stock Exchange - Main Market |
|
c) |
Number of further securities issued and admitted |
14,807 |
|
d) |
Total number of securities in issue following admission |
1,550,995,630 |
|
e) |
Fungibility |
Fully fungible with existing Ordinary Shares |
|
3 |
Admission details |
|
|
a) |
Date of admission |
Issued between 1 April 2026 to 30 April 2026 (admitted under a block admission dated 29 January 2021) |
|
b) |
Prospectus information |
Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
|
|
c) |
Coverage of notification |
Admission of shares under the Company's employee share schemes from 1 April 2026 up to 30 April 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021. |
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund